[General childhood vaccination against HPV 16 and 18 aimed at preventing cervical cancer]

Swedish Council on Technology Assessment in Health Care
Record ID 32008100071
Original Title: Allmän barnvaccination mot HPV 16 och 18 i syfte att förebygga livmoderhalscancer
Authors' recommendations: Summary and Conclusions: SBU’s appraisal of the evidence: Vaccination against viral infections is a relatively new principle for cancer prevention. Vaccines against human papilloma virus (HPV) are aimed at preventing cervical cancer. Current vaccines target HPV types 16 and 18 and not all cervical cancer-associated HPV types. In young women1 showing no signs of past or current HPV 16 or 18 infection at the onset of the study, vaccination provided over 90% protection against high-grade cervical intraepithelial neoplasias (CIN) positive for HPV 16 or 182 (Evidence Grade 1)*. These study results currently offer the closest estimate of the expected preventive effect of vaccinating children. After vaccination, children initially developed an immune response that was equal or superior to that achieved in young women after vaccination2 (Evidence Grade 2)*. The effect of general childhood vaccination against HPV 16 and 18 on future morbidity and mortality from cervical cancer in Sweden is not yet known. One estimate shows that nearly half of the cervical cancer cases would not be prevented by general childhood vaccination against HPV 16 and 18. Therefore organized cervical cancer screening programs would need to continue. The effect of general childhood vaccination against HPV 16 and 18 on the willingness of vaccinated women to participate in organized screening programs would need to be determined. Scientific evidence on the cost-effectiveness of general childhood vaccination against HPV 16 and 18, in combination with organized cervical cancer screening programs, is uncertain and therefore found to be insufficient. Whether or not vaccine against HPV 16 and 18 should be included in the Swedish general vaccination program is a policy issue that concerns, among other things, the level of uncertainty that the public can accept regarding positive and negative effects when allocating resources. Introducing such a program would require organized, systematic followup of the outcomes and cost-effectiveness of all preventive interventions against cervical cancer.
Authors' methods: Review
Project Status: Completed
Year Published: 2008
URL for published report: https://www.sbu.se/200801e
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Sweden
MeSH Terms
  • Papillomavirus Vaccines
  • Uterine Cervical Neoplasms
  • Child
  • Adolescent
  • Vaccination
  • Papillomavirus Infections
Organisation Name: Swedish Agency for Health Technology Assessment and Assessment of Social Services
Contact Address: P.O. Box 3657, SE-103 59 Stockholm, Sweden. Tel: +46 8 4123200, Fax: +46 8 4113260
Contact Name: registrator@sbu.se
Contact Email: registrator@sbu.se
Copyright: Swedish Council on Technology Assessment in Health Care (SBU)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.